Cidara Therapeutics (CDTX) said Monday that its phase 2b trial evaluating CD388, its long-acting antiviral for seasonal influenza prevention, met its primary and secondary endpoints.
The study showed that a single dose of CD388 provided 76.1% protection at 450 mg, 61.3% at 300 mg, and 57.7% at 150 mg against symptomatic influenza over 24 weeks.
CD388 was well tolerated with no adverse events observed, the company said.
Cidara said it has submitted an end-of-phase 2 meeting request to the US Food and Drug Administration to discuss plans for a phase 3 trial.
Cidara shares surged 83% in pre-market trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.